# NuCana Appoints Ian Webster as Chief Financial Officer
Canonical URL: https://biopharmsignal.com/news/NCNA/nucana-appoints-ian-webster-as-chief-financial-officer
Ticker: NCNA
Company: NuCana plc
Source: NuCana plc
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.nucana.com
## Summary

EDINBURGH, United Kingdom, June 01, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster as Chief Financial

## Article Body
EDINBURGH, United Kingdom, June 01, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster as Chief Financial
## Recent Company News
- 2026-06-25 13:46 EST — [NuCana Appoints Ian Webster as Chief Financial Officer](https://biopharmsignal.com/news/NCNA/nucana-appoints-ian-webster-as-chief-financial-officer) — Source: NuCana plc
- 2026-06-25 13:46 EST — [NuCana Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/NCNA/nucana-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: NuCana plc
- 2026-06-25 13:46 EST — [NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/NCNA/nucana-reports-second-quarter-2025-financial-results-and-provides-business-update) — Source: NuCana plc
- 2026-06-25 13:46 EST — [NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025](https://biopharmsignal.com/news/NCNA/nucana-to-present-data-on-nuc-7738-s-synergy-with-pd-1-inhibitors-at-the-esmo-congress-2025) — Source: NuCana plc
- 2026-06-25 13:46 EST — [NuCana Compliant with All Nasdaq Continued Listing Criteria](https://biopharmsignal.com/news/NCNA/nucana-compliant-with-all-nasdaq-continued-listing-criteria) — Source: NuCana plc
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)